Head-to-head comparison
| Property | MGF | PEG-MGF |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Research Only | Research Only |
| Primary Route | intramuscular | subcutaneous |
| Half-life | Native MGF: minutes; PEG-MGF: several days (pegylation dramatically extends duration) | ~24–72 hours (PEGylated; native MGF half-life is ~5–7 minutes) |
| Mol. Weight | 2,867.2 Da | 2,867.2 Da |
| Side Effects | Injection site pain or swelling, Hypoglycemia (theoretical, shared with IGF-1 family), Local tissue growth at injection site (with repeated IM injection) | Injection site pain or swelling, Hypoglycemia risk (IGF-1 pathway activity), Water retention |
Key differences
- Half-life: Native MGF has a half-life of approximately 5-7 minutes; PEG-MGF extends this to an estimated 24-72 hours through polyethylene glycol conjugation.
- Mechanism: Both work through the same MGF E-peptide that activates quiescent satellite cells, but PEG-MGF also binds IGF-1 receptors directly and triggers Akt/mTOR and MAPK/ERK signaling due to its prolonged systemic presence.
- Route: Native MGF is typically injected intramuscularly into target muscles post-workout; PEG-MGF can be administered subcutaneously or intramuscularly with systemic distribution.
- Dosing frequency: Native MGF requires injection 2-3 times per week immediately post-workout due to its rapid degradation; PEG-MGF is dosed 2-3 times per week without timing constraints.
- Effect scope: Native MGF produces localized effects at the injection site due to rapid clearance; PEG-MGF provides more sustained systemic satellite cell activation.
- Evidence: Both lack human clinical trials; in vitro data shows native MGF E-peptide increases satellite cell proliferative lifespan at concentrations as low as 3 ng/ml.
- Legal status: Both are research-only compounds, prohibited by WADA in competitive sport, with no FDA-approved medical use.
The verdict
MGF and PEG-MGF share the same biological target — muscle satellite cell activation — but differ in how long they remain active. Native MGF's minutes-long half-life makes it suited for localized, post-workout injection protocols, while PEG-MGF's extended half-life of 24-72 hours allows less frequent dosing with broader tissue exposure. Neither has completed human clinical trials, so the practical advantages of one form over the other remain based on pharmacokinetic reasoning rather than comparative clinical evidence.
Frequently asked questions
PEG-MGF has a dramatically longer half-life (24-72 hours vs minutes), which provides sustained exposure to muscle tissue. Whether this translates to greater effectiveness is not established by clinical data. Native MGF may provide more intense localized effects at the injection site due to its concentrated burst of activity.
Some research protocols combine native MGF (for localized post-workout satellite cell activation) with PEG-MGF (for sustained systemic effects). No controlled studies validate this combination. The rationale is similar to combining short-acting and long-acting forms of other peptides.
Native MGF has a half-life of only about 5-7 minutes, so intramuscular injection directly into target muscle groups is intended to maximize local satellite cell activation before the peptide is degraded. Subcutaneous injection would result in most of the peptide being cleared before reaching muscle tissue.
PEGylation attaches polyethylene glycol molecules to the peptide, which shields it from proteolytic degradation and reduces renal clearance. This extends the half-life from approximately 5-7 minutes to an estimated 24-72 hours, allowing the peptide to circulate and reach multiple tissue sites.
Human safety data is limited for both forms. Reported side effects include injection site pain or swelling, theoretical hypoglycemia risk (shared with the IGF-1 family), and localized tissue growth with repeated IM injection. PEG-MGF has a theoretical concern about accelerating existing neoplastic tissue growth. No human clinical trials have been completed for either form.